文献速递眼底病与葡萄膜炎眼整形与眼眶神经眼科

印度一家多专科三级医疗中心COVID-19后毛霉病的累积死亡率及与结局相关的因素

Cumulative Mortality and Factors Associated With Outcomes of Mucormycosis After COVID-19 at a Multispecialty Tertiary Care Center in India.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

这项在印度西部一家三级多专科医院开展的回顾性病例对照研究纳入73例COVID-19相关鼻-眶-脑毛霉病(CAM)患者,26例(36%)死亡,死亡累积概率第7天为26%、第21天升至53%。多因素Cox回归显示既往接受机械通气与死亡风险近9倍升高相关,视力为光感或更好者死亡风险降低46%。

要点

  • 73例CAM患者中26例(36%)死亡,死亡累积概率第7天26%、第21天53%。
  • 既往机械通气者死亡风险近9倍升高(HR 8.98),视力光感或更好者死亡风险降低46%(HR 0.56)。
  • 静脉两性霉素B与需眶内容物剜除率降低相关(0 vs 5/25[20%],P<.001)。

核心结论

  • 作者认为鼻-眶-脑毛霉病后死亡率高,重症COVID-19或表现为严重眼眶病变的亚组患者更可能在入院10天内死亡。

研究设计与样本

  • 回顾性病例对照研究,2021年3月1日至5月30日在印度西部一家三级多专科医院开展。
  • 纳入所有诊断为CAM且随访至少30天或30天内因CAM死亡的患者,共73例连续患者,平均(SD)年龄53.5(12.5)岁,其中48例(66%)为男性。

主要发现

  • CAM在COVID-19康复后中位28天(IQR 15-45;范围4-90)发生。
  • 73例CAM患者中26例(36%)死亡;死亡累积概率第7天为26%(95%CI 16%-41%),第21天翻倍至53%(95%CI 39%-69%)。
  • 51例中18例(35%)行鼻窦清创术,52例中5例(10%)行眶内容物剜除术,48例(66%)接受静脉注射冻干两性霉素B。
  • 多因素Cox比例风险回归显示,既往接受机械通气与死亡风险近9倍升高相关(HR 8.98;95%CI 2.13-38.65;P=.003),视力为光感或更好者死亡风险降低46%(HR 0.56;95%CI 0.32-0.98;P=.04)。
  • 静脉两性霉素B给药与眶内容物剜除率降低相关(0 vs 5/25[20%];P<.001);多因素分析中接受静脉两性霉素B者死亡风险降低69%(HR 0.31;95%CI 0.06-1.43;P=.13)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: An outbreak of COVID-19-associated rhino-orbitocerebral mucormycosis (CAM) has occurred in many parts of the world. Although the clinical profile and risk factors for CAM have been studied, cumulative mortality and its risk factors have not. OBJECTIVE: To report the cumulative mortality rates at different times in cases with CAM and identify risk factors for CAM-associated mortality. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case-control study was conducted from March 1 to May 30, 2021, in a tertiary care multispecialty hospital in western India. All patients diagnosed with CAM and with a minimum follow-up of 30 days or those who died before 30 days due to CAM were included. MAIN OUTCOMES AND MEASURE: Cumulative mortality in CAM using survival analysis. RESULTS: A total of 73 consecutive patients with CAM with a mean (SD) age of 53.5 (12.5) years were included in the analysis, of whom 48 (66%) were men. CAM developed at a median of 28 (IQR, 15-45; range, 4-90) days after recovery from COVID-19. Of the 73 patients with CAM, 26 (36%) died; the cumulative probability of death was 26% (95% CI, 16%-41%) at day 7 and doubled to 53% (95% CI, 39%-69%) at day 21. Sinus debridement was performed in 18 of 51 patients (35%), and 5 of 52 (10%) underwent exenteration, whereas intravenous lyophilized amphotericin B was administered to 48 patients (66%). A multivariate Cox proportional hazards regression analysis showed that receiving mechanical ventilation in the past was associated with a nearly 9-fold increased risk of death (hazard ratio [HR], 8.98; 95% CI, 2.13-38.65; P = .003), and patients who had visual acuity of light perception or better had a 46% lower risk of death (HR, 0.56; 95% CI, 0.32-0.98; P = .04). Intravenous amphotericin B administration was associated with a reduced rate of exenteration (0 vs 5 of 25 [20%]; P < .001). On multivariate analysis, those who received intravenous amphotericin B had a 69% reduced risk of death (HR, 0.31; 95% CI, 0.06-1.43; P = .13). CONCLUSIONS AND RELEVANCE: These findings suggest that the mortality rate after rhino-orbitocerebral mucormycosis is high and that a subgroup of patients with severe COVID-19 or presenting with severe orbital disease are more likely to die within 10 days of admission.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Choksi T, Agrawal A, Date P, et al. Cumulative Mortality and Factors Associated With Outcomes of Mucormycosis After COVID-19 at a Multispecialty Tertiary Care Center in India. JAMA Ophthalmol. 2022. PMID: 34882192. doi:10.1001/jamaophthalmol.2021.5201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。